Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 2/20 | 0.46 |
| ▸ | HRAS | P01112 | 1/20 | 0.46 |
| ▸ | HK1 | P19367 | 2/20 | 0.45 |
| ▸ | HK2 | P52789 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9746872 | 0.88 | HK1 (0.58) | LGALS8HRASHK1HK2ALDH1A1 | |
| SCHEMBL18803484 | 0.88 | HK1 (0.58) | LGALS8HRASHK1HK2ALDH1A1 | |
| SCHEMBL12812847 | 0.88 | HK1 (0.58) | LGALS8HRASHK1HK2ALDH1A1 | |
| SCHEMBL10522400 | 0.88 | HK1 (0.58) | LGALS8HRASHK1HK2ALDH1A1 | |
| SCHEMBL7147563 | 0.88 | HK1 (0.58) | LGALS8HRASHK1HK2ALDH1A1 | |
| SCHEMBL10521162 | 0.88 | HK1 (0.58) | LGALS8HRASHK1HK2ALDH1A1 | |
| SCHEMBL15763312 | 0.88 | HK1 (0.58) | LGALS8HRASHK1HK2ALDH1A1 | |
| SCHEMBL14780667 | 0.88 | HK1 (0.58) | LGALS8HRASHK1HK2ALDH1A1 | |
| SCHEMBL374488 | 0.88 | HK1 (0.58) | LGALS8HRASHK1HK2ALDH1A1 | |
| SCHEMBL8537938 | 0.86 | LGALS8 (0.61) | LGALS8HRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059842-B2 | Monosaccharide amine and 3-nitro-2-phenyl-2H-chromene based inhibitors of glucose kinases | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200339619-A1 | Monosaccharide Amine and 3-Nitro-2-Phenyl-2H-Chromene Based Inhibitors of Glucose Kinases | UNIVERSITY OF SOUTH CAROLINA | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339619-A1 | Monosaccharide Amine and 3-Nitro-2-Phenyl-2H-Chromene Based Inhibitors of Glucose Kinases | GALK1, GCK, FN3K | LGALS8 572/4885NAAA 863/4885HRAS 3958/4885 |
| US-11059842-B2 | Monosaccharide amine and 3-nitro-2-phenyl-2H-chromene based inhibitors of glucose kinases | GALK1, GCK, FN3K | LGALS8 572/4885NAAA 863/4885HRAS 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.